N-(3-乙基苯基)-5-氯-2-羟基苯甲酰胺 | 1036462-19-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-乙基苯基)-5-氯-2-羟基苯甲酰胺
• 英文名称: N-(3-ethylphenyl)-5-chloro-2-hydroxybenzamide
• 英文别名: 5-Chloro-2-hydroxy-N-(3-ethylphenyl)benzamide；5-chloro-N-(3-ethylphenyl)-2-hydroxybenzamide
• CAS: 1036462-19-7
• 化学式: C₁₅H₁₄ClNO₂
• 分子量: 275.735
• InChiKey: FHQMKXAFCOCOSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氯代水杨酸 、 3-乙基苯胺 生成 N-(3-乙基苯基)-5-氯-2-羟基苯甲酰胺
  参考文献：
  名称：

  Glutamate receptor modulators and therapeutic agents

  摘要：

  本发明揭示了使用一类定义的苯甲酰胺化合物调节I类mGluR活性的方法。在一种实施例中，提供了调节mGluR1活性的方法。在另一种实施例中，提供了调节mGluR5活性的方法。在另一种实施例中，提供了同时调节mGluR1和mGluR5活性的方法。本发明还提供了使用属于定义的苯甲酰胺化合物类别中的一个或多个化合物治疗完全或部分通过I类mGluR介导的疾病或障碍的方法。本发明还提供了使用属于定义的化合物类别中的一个或多个化合物预防完全或部分通过I类mGluR介导的疾病或障碍的方法。考虑到的疾病和障碍包括中枢神经系统、外周神经系统、胃肠系统、循环系统、皮肤、视网膜、大脑、心脏和肺等疾病和障碍。

  公开号：

  US20090239919A1

文献信息

• Glutamate receptor modulators and therapeutic agents
  申请人：Wood Richard Delarey

  公开号：US20090239919A1

  公开（公告）日：2009-09-24

  The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.

  本发明公开了利用一类明确定义的苯甲酰胺化合物调节I类mGluRs活性的方法。在一个实施例中，提供了调节mGluR1活性的方法。在另一个实施例中，提供了调节mGluR5活性的方法。在另一个实施例中，提供了同时调节mGluR1和mGluR5活性的方法。本发明还提供了利用属于明确定定义的苯甲酰胺化合物类的一个或多个化合物治疗由I类mGluRs完全或部分介导的疾病或紊乱的方法。本发明还提供了利用属于明确定定义的化合物类的一个或多个化合物预防由I类mGluRs完全或部分介导的疾病或紊乱的方法。所考虑的疾病和紊乱包括中枢神经系统、外周神经系统、胃肠系统、循环系统、皮肤、视网膜、大脑、心脏和肺等疾病和紊乱。
• Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals
  申请人：Wood Richard Delarey

  公开号：US20130324555A1

  公开（公告）日：2013-12-05

  The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.

  本发明涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物，单独使用或与一个或多个其他活性或辅料药物物质结合使用。本发明进一步涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物的组合。本发明进一步涉及有效药物配方的使用方法，用于治疗由顶复门寄生虫引起的疾病。该配方包括本文所披露的水杨基苯胺或水杨基苯胺衍生物的组合，进一步包含一个或多个活性或辅料药物物质。
• US8211882B2
  申请人：——

  公开号：US8211882B2

  公开（公告）日：2012-07-03
• US8614205B2
  申请人：——

  公开号：US8614205B2

  公开（公告）日：2013-12-24
• [EN] GLUTAMATE RECEPTOR MODULATORS AND THERAPEUTIC AGENTS<br/>[FR] MODULATEURS DES RÉCEPTEURS AU GLUTAMATE ET AGENTS THÉRAPEUTIQUES
  申请人：WOOD RICHARD D

  公开号：WO2010101648A1

  公开（公告）日：2010-09-10

  The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs.